Ozempic babies: separating fertility fact from TikTok fiction

What did @drkaisrona actually say?

The video makes four claims about so-called "Ozempic babies": that there's no direct scientific proof GLP-1 drugs increase pregnancy risk, that the effect is physiologically plausible through two pathways, that non-oral contraception is the practical fix, and that GLP-1s should be stopped if pregnancy occurs. The creator is a doctor speaking to 164,000 viewers, so precision matters here.

To give credit upfront: the overall framework is reasonable and more cautious than most TikTok content on this topic. But a few specific claims need closer scrutiny, particularly around oral contraceptive absorption and the framing of stopping medication as "not a good option."

Does the science back this up?

The core claim, that weight loss from GLP-1s may restore ovulation in people with obesity-related anovulation, is well-supported. The claim about oral contraceptive absorption interference is plausible but overstated given current evidence.

Obesity disrupts the hypothalamic-pituitary-ovarian axis through hyperinsulinemia, elevated androgens, and leptin resistance. GLP-1 receptor agonists address some of these pathways, and weight loss itself reliably improves menstrual regularity. A 2023 review by Joham et al. in The Lancet Diabetes and Endocrinology confirmed that weight reduction significantly improves ovulation rates in people with PCOS, the most common obesity-linked fertility condition.

The oral contraceptive absorption argument is where things get shakier. Semaglutide slows gastric emptying, which could theoretically reduce peak plasma concentrations of oral contraceptives. A pharmacokinetic substudy in the SUSTAIN trials did show modest reductions in levonorgestrel and ethinyl estradiol exposure. However, Rosenstock et al. (2023, Diabetes Care) noted these reductions were not consistently clinically significant. The FDA label for semaglutide acknowledges the interaction but stops short of recommending contraceptive switching for everyone.

What did they get wrong (or right)?

The creator gets the fertility mechanism mostly right but overstates the oral contraceptive risk. Saying that slowed gut digestion "can affect the absorption" of oral contraceptives is technically accurate. But the video implies this effect is strong enough to explain a meaningful increase in contraceptive failures, and that evidence simply does not exist yet.

The framing that "stopping the medication is not a good option" because "patients want to lose weight" is a notable misstep. That's a patient preference argument, not a clinical one. There are real clinical reasons someone might continue or discontinue, including cardiovascular risk profile and diabetes management needs. Centering the reason as patient desire to lose weight reduces a complex clinical decision to aesthetics.

What the video gets right: recommending IUDs or implants over pills is clinically sound advice for anyone on a gastric-motility-altering drug. The recommendation to stop GLP-1s during pregnancy is also correct. Animal studies have shown fetal harm at high doses, and there are no adequate human pregnancy safety data for semaglutide or tirzepatide. The FDA label for Wegovy explicitly advises discontinuation at least two months before planned conception.

What should you actually know?

If you're on a GLP-1 and using oral contraceptives, this is a real conversation to have with your prescriber, but don't panic based on a TikTok video. The pharmacokinetic interaction exists; its real-world impact on contraceptive failure rates is not yet quantified in large studies.

If you become pregnant while on a GLP-1, stopping the medication is the right call. This isn't a fringe opinion; it's the manufacturer recommendation and the consensus of major endocrinology societies. The Endocrine Society's 2023 obesity pharmacotherapy guidelines state that GLP-1 receptor agonists should be discontinued upon confirmed pregnancy.

• People with PCOS or obesity-related irregular cycles may ovulate more regularly once they start losing weight on a GLP-1, sometimes faster than expected.
• The gastric emptying effect of semaglutide is dose-dependent and most pronounced in the first months of treatment.
• Long-acting reversible contraceptives (IUDs, implants) are unaffected by gut motility, making them a practical choice for people on GLP-1 therapy who want reliable contraception.
• No published population-level data yet confirms a statistically significant increase in unintended pregnancy rates among GLP-1 users compared to controls.